Request Information
![image of Biologic Treatment of Pediatric Inflammatory Bowel Disease: A Decade of JPGN Contributions](https://d1s7nfzf0sunp3.cloudfront.net/13220.jpg)
Biologic Treatment of Pediatric Inflammatory Bowel Disease: A Decade of JPGN Contributions
- Publication Year:
- 2014
- Edition:
- 1st
- Author:
- Heyman, Melvin B.; Shamir, Raanan
- Publisher:
- Lippincott Williams & Wilkins (LWW)
- ISBN:
- 978-1-46-988716-6
-
Description
-
Details
-
Collections
-
Also Recommended
Description
This collection of articles from JPGN represent seminal work on the application, safety, and efficacy of the 2 leading anti-TNF agents, infliximab and adalimumab, to assist readers in considering treatment options and further advances in the care of pediatric patients with chronic IBD.
Drug development in children and adolescents occasionally is hindered by a hesitance to expose young patients to experimental and untested therapies. A case in point is the application of biologic agents in the management of pediatric patients with inflammatory bowel disease (IBD). The degree of acceptance of antitumor necrosis factor (TNF) agents after their introduction as a novel treatment option has ranged from initial enthusiasm to caution resulting from fear of complications such as hepatosplenic T-cell lymphoma (HSTCL) to approval as part of standard management. In fact, as we gather additional experience and evidence, a trend toward the use of biologic agents as a first-line treatment has emerged.
Drug development in children and adolescents occasionally is hindered by a hesitance to expose young patients to experimental and untested therapies. A case in point is the application of biologic agents in the management of pediatric patients with inflammatory bowel disease (IBD). The degree of acceptance of antitumor necrosis factor (TNF) agents after their introduction as a novel treatment option has ranged from initial enthusiasm to caution resulting from fear of complications such as hepatosplenic T-cell lymphoma (HSTCL) to approval as part of standard management. In fact, as we gather additional experience and evidence, a trend toward the use of biologic agents as a first-line treatment has emerged.
Details
- Platform:
- OvidSP
- Publisher:
- Lippincott Williams & Wilkins (LWW)
- Product Type:
- Book
- Author:
- Heyman, Melvin B.; Shamir, Raanan
- ISBN:
- 978-1-46-988716-6
- Specialty:
-
- Internal Medicine
- Pediatrics
- Language:
- English
- Edition:
- 1st
- Pages:
- 148
- Publication Year:
- 2014
- Advances in Surgical Pathology: Endometrial Carcinoma
- Advances in Surgical Pathology: Gastric Cancer
- Advances in Surgical Pathology: Prostate Cancer
- Alzheimer's Care Today
- Atlas of Oral and Maxillofacial Histopathology
- Cardiac Care Unit Survival Guide, The
- Clinical Scenarios in Surgery: Decision Making and Operative Technique
- Complications in Regional Anesthesia and Pain Medicine
- Cutaneous Adnexal Tumors
- Evidence-Based Endocrinology
- Foot & Ankle Sports Medicine
- Harris & Harris' Radiology of Emergency Medicine
- Learning Strabismus Surgery: A Case-Based Approach
- Lippincott's Manual of Toxicology
- Manual of Cardiovascular Medicine
- Master Techniques in Surgery: Gastric Surgery
- Master Techniques in Surgery: Hernia
- Mathog's Atlas of Craniofacial Trauma
- Neurology Clinical Practice
- Neuropathologic Evaluation: From Pathologic Features to Diagnosis
- Operative Techniques in Spine Surgery
- Pediatric Hand and Upper Limb Surgery: A Practical Guide
- Photographic Atlas of Pediatric Disorders and Diagnosis
- Practical Guide to Chemical Peels, Microdermabrasion & Topical Products, A
- Shnider and Levinson's Anesthesia for Obstetrics
- Shoulder, The
- Sports Medicine Conditions: Return To Play: Recognition, Treatment, Planning
- Vascular Access: Principles and Practice
- Visual Diagnosis and Care of the Patient with Special Needs
- Washington Manual of Critical Care, The